Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 69,582 Shares

Royalty Pharma PLC (NASDAQ:RPRX) CFO Terrance Coyne sold 69,582 shares of Royalty Pharma stock in a transaction on Monday, November 24th. The stock was sold at an average price of $38.55, for a total value of $2,682,386.10. Following the sale, the chief financial officer owned 51,010 shares in the company, valued at $1,966,435.50. The trade was a 57.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $39.84 on Thursday. The company has a market capitalization of $23.00 billion, a PE ratio of 30.18, a price-to-earnings-growth ratio of 2.08 and a beta of 0.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma PLC has a 52-week low of $24.05 and a 52-week high of $41.24. The company has a 50-day simple moving average of $37.30 and a 200 day simple moving average of $36.05.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The company had revenue of $609.29 million during the quarter, compared to analyst estimates of $765.01 million. On average, research analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 14th. Royalty Pharma’s dividend payout ratio is presently 66.67%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on RPRX shares. The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 target price on the stock. Morgan Stanley decreased their price objective on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Weiss Ratings lowered Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Finally, TD Cowen cut Royalty Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 17th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Royalty Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $46.00.

Hedge Funds Weigh In On Royalty Pharma

A number of institutional investors have recently made changes to their positions in RPRX. Smartleaf Asset Management LLC lifted its stake in shares of Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Royalty Pharma in the second quarter valued at about $32,000. Financial Consulate Inc. bought a new position in shares of Royalty Pharma during the third quarter valued at about $35,000. Summit Securities Group LLC bought a new stake in shares of Royalty Pharma in the first quarter worth about $36,000. Finally, WPG Advisers LLC bought a new position in Royalty Pharma during the 1st quarter valued at approximately $39,000. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.